sdü tıp fak derg

Medical Journal of Süleyman Demirel University

2602-2109

Süleyman Demirel Üniversitesi

10.17343/sdutfd.1209482

Surgery

Cerrahi

PROSTAT-SPESİFİK MEMBRAN ANTİGEN MENENGİOM TEDAVİSİNDE YER ALABİLİR Mİ?

CAN PROSTATE-SPECIFIC MEMBRANE ANTIGENE TAKE PART IN MENENGIOMA TREATMENT?

https://orcid.org/0000-0002-1735-4062

Oğuzoğlu

Ali Serdar

SÜLEYMAN DEMİREL ÜNİVERSİTESİ

https://orcid.org/0000-0002-1714-3150

Şenol

Nilgün

SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ

https://orcid.org/0000-0002-5470-6784

Yasan

Hasan

SÜLEYMAN DEMİREL ÜNİVERSİTESİ

https://orcid.org/0000-0002-9418-8862

Yüceer

Ramazan Oğuz

SÜLEYMAN DEMİREL ÜNİVERSİTESİ

https://orcid.org/0000-0002-5619-4989

Çiriş

İbrahim Metin

SÜLEYMAN DEMİREL ÜNİVERSİTESİ

09 23 2023

30 3 302 307 11 24 2022 07 27 2023

1994

Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

AmaçTümör oluşumunda ve ayırıcı tanısında tümör anjiogeneziönemli bir unsur ve değerli bir göstergedir.Menengiomlar vasküleritesi yüksek tümörler olmasınedeni ile bu çalışmada, farklı tedavi protokolleriningeliştirilebilmesi açısından menengiomlarda immunohistokimyasalyöntemlerle prostat-spesifik membranantijen (PSMA) salınımının değerlendirilmesi amaçlanmıştır.Gereç ve YöntemKliniğimizde opere edilerek Derece I (n=32), Derece II(n=6) ve Derece III (n=10) menengiom tanısı almış 48hastadan alınmış olan doku örneklerinde PSMA antikorlarıimmunohistokimyasal metod ile incelendi. Tümördokusundaki PSMA boyanma yoğunluğu ve yüzdesiincelendi. Tümör epitelinde tümör ve tümör-dışıdokuda PSMA salınımına göre vasküler salınım veyoğunluk skoru analiz edildi.BulgularFarklı derecelerdeki menengiom preparatlarında yapılanimmunohistokimyasal analizler tümör epitelindeve stromasında PSMA salınım ve yoğunluk skorlarıarasında istatistiksel olarak anlamlı farklılık olmadığınıgösterdi (p>0.05).SonuçAgresif seyreden, rezeke edilemeyen menegiomlardaanjiogeneziste rol alan bazı moleküler biomarkerlarönem kazanmaktadır. Her ne kadar PSMA açısındananlamlı sonuçlar elde edilmemiş olsa da moleküler vegenetik teknikler geliştikçe tümör biyolojisinin ortayakonup potansiyel hedeflerin belirlenmesi yeni tedaviyolları açacaktır.

ObjectiveIn tumor development, tumor angiogenesis is anessential component, and a valuable marker in thedifferantial diagnosis of brain tumors. As menengiomasare highly vascular tumors in this study, we aimedto evaluate the expression of prostate-spesificmembrane antigen (PSMA) in menengiomas byimmunohistochemistry method to determine differenttarget therapies.Material and MethodPathologic specimens with the diagnosis Grade I(n=32), Grade II (n=6) ve Grade III (n=10) of 48 patientsoperated for menengioma in our clinic, were evaluatedfor PSMA-antibody via immunohistochemical method.PSMA staining intensities in tumor tissue and tumorepithelium were analyzed. Vascular expression intumoral and extratumoral stroma, and intensity score,according to PSMA expression, in tumoral epitheliumwere analyzed.ResultsImmunohistochemical analyses of different grademenengioma specimens showed no statisticallysignificant differences between PSMA expression andPSMA staining intensities in tumor tissue and tumorepithelium (p>0.05).ConclusionSome molecular biomarkers, that take part inangiogenesis of agressive and unresectablemenengiomas come into prominence. Although nosignificant results were achieved in terms of PSMA, asthe molecular and genetic techniques progress, tumorbiology manifestation and determination of potentialtargets will lead to new treatment procedures.

menengiom antijen prostat-spesifik membran anjiogenez

menengioma antigen prostate-spesific membrane angiogenesis

Süleyman Demirel Üniversitesi Bilimsel Araştırma Projeleri

TSG 2020-8134 numara

1. Martinez NL, Khanna O, Farrell CJ. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniophargyngioma of the skull base. Chin Clin Oncol 2020;9(6):75.

2. Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS Statistical report: primary brian and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol 2019;21:v1-v100.

3. Matsuda M, Ishikawa E, Yamamoto T, Hatano K, Joraku A, Lizumi Y, Masuda Y, Nishiyama H, Matsumara A. Potential use of prostate spesific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with ⁸⁹Zr-Df-IAB2M anti-PSMA minibody. J of Neuro-Oncology 2018;138:581-589.

4. Akhtar NH, Pail O, saran A, et al. Prostate-spesific membrane antigen based therapeutics. Advanced in Urology. 2012;2012:973820. doi: 10.1155/2012/973820.

5. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–35.

6. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor- associated neovasculature. Cancer Res. 1999;59:3192–8.

7. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate- specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629–34.

8. Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, Chen Y, Yang X, Cho SY, Nimmagadda S, Pomper MG. Prostate spesific membrane antigen as a target for cancer imaging and therapy. Quart J Nucl Med Mol Imaging 2015;59:241-268.

9. Pandit-Taskar N, O’Donoghue JA, Ruan S, Lyanshchenko SK,- Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE et al. First in human imaging with ⁸⁹Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J Nucl Med 2016;57:1858-1864.

10. Nomura N, Pastorino S, Jiang P, et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastasis. Caner Cell International. 2014;14.

11. Wernicke AG, Edgar MA, Lavi E, et al. Prostate Specific Membrane Antigen as a potential Novel Vascular Target for Treatment of Glioblastoma Multiforme. Aarchives of Pathology and Laboratory Medicine. 2011;135:1486–9.

12. Mahzouni P, Shavakhi M. Prostate-spesific membrane antigen expression in neovasculature of glioblastoma multiforme. Adv Biomed Res. 2019;8:18.

13. Wernicke AG, Varma S, Greenwood EA et al Prostate‐specific membrane antigen expression in tumor‐associated vasculature of breast cancers. Apmis 2014;122(6):482-9.

14. Wernicke AG, Kim S, Liu H, Bander NH, Pirog EC Prostate- specific membrane antigen (PSMA) expression in the neovasculature of gynecologic malignancies: implications for PSMA-targeted therapy. Immunohistochemistry & Molecular Morphology. 2017;25(4):271-6.

15. Barresi V. Angiogenesis in meningiomas. Brain Tumor Pathol 2011;28:99-106.

16. Chang SS, Keefe DSO, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-spesific membrane antigen is produced in tumor-associated neovasculature. Clin cancwer Res. 1999;5(10):2674-81.

17. Tubre T, Hacking S, Alexander A, et al. Prostate-Specific Membrane Antigen Expression in Meningioma: A Promising Theranostic Target. J neuropathol Exp Neurol 2022;81(12):1008- 1017.

18. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;24:486–495.

19. Mettler F, Guiberteau M. Essentials of nuclear medicine and molecular imaging. 7th ed. Philadelphia, PA: Elsevier, 2019.

20. Gupta N, Verma R, Belho ES. Prostate-Specific Membrane Antigen-Avid Meningioma Detected in 68Ga-Prostate-Specific Membrane Antigen PET/CT. Clin Nucl Med 2020; 45(9): 692- 693.

21. Haemels M, jentjens S, Cleeren F, et al. All that glitters is not prostate cancer: incidental finding of PSMA-avid meningioma. Hell J Nucl Med 2020;23(1):79-80.

22. Jiang JY, Yip JWL, Kang C, et al. Incidental prostate-specific membrane antigen-avid meningioma detected on 68Ga-prostate-specific membrane antigen PET/CT. Radiol Case Rep 2021;16(11):3422-3425.

23. Junqueira MZ, Rocha NH, Sapienza MT. 68Ga-Prostate-Specific Membrane Antigen PET/CT Uptake in Intraventricular Meningioma in the Choroid Plexus. Clin Nuck Med 2021;46(1):58- 59.

24. de Galiza Barbosa F, Queiroz MA, Nunes RF, et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imag 2020;20: 23.

25. Bilgin R, Ergül N, Çermik TF. Incidental meningioma mimicking metastasis of prostate adenocarcinoma in ⁶⁸Ga-labeled PSMA PET/CT. Clinical Nuclear Medicine 2016;41(12):956-958.

26. Meewes C., Bohuslavizki K. H., Krisch B., Held-Feindt J., Henze E., Clausen M. Molecular biologic and scintigraphic analyses of somatostatin receptor-negative meningiomas. Journal of Nuclear Medicine. 2001;42(9):1338–1345.